DOP067 Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: a comparative effectiveness study of vedolizumab vs. infliximab

Abstract

Background: Current inflammatory bowel disease (IBD) treatment guidelines recommend the gut-selective anti-integrin antibody vedolizumab (VDZ) for treatment of patients with moderately to severely active disease who have had an inadequate response with, lost response to, or were intolerant to a tumour necrosis factor antagonist such as infliximab (IFX). We evaluated clinical outcomes of VDZ vs. IFX over the first year of treatment to assess their effectiveness as initial therapy. Method(s): Biologic-naive patients with IBD who initiated VDZ or IFX treatment between May 2014 and April 2017 were identified from the Explorys Universe database. Patients included were aged >=18 years and had: >=365 days of medical history at index date (date of the first infusion); >=188 days of follow-up; successfully completed the induction phase and moved to maintenance therapy (>=3 infusions